The Netherlands
Sabiad is a promising startup focused on developing localized theranostic solutions specifically for orthopedic implant infections. Utilizing advanced molecular imaging techniques, the company leverages monoclonal antibodies to both detect and treat infections caused by Staphylococcus aureus in implant-related scenarios.
Founded in 2022, Sabiad stands at the forefront of a niche yet critical sector within the healthcare industry, addressing a significant medical challenge. While details about its base of operations remain under wraps, the company recently received investment from Pharma Connect Capital on 01 January 2024, signaling increasing investor confidence in its innovative approach.
Though specific industry categorizations are absent, the potential impact of Sabiad's solutions aligns with growing global concerns around antibiotic resistance and post-operative recovery complications. With its novel focus on theranostics, this startup represents a compelling opportunity for investors interested in pioneering medical breakthroughs.
